◐ Shell
reader mode source ↗
Jump to content
From Wikipedia, the free encyclopedia

Pharmaceutical compound
LY03020
Clinical data
Other namesLY-03020; LPM787000048; LPM-787000048
Routes of
administration		Oral
Drug classSerotonin 5-HT2C receptor agonist
ATC code
  • None

LY03020 is a dual serotonin 5-HT2C receptor agonist and trace amine-associated receptor 1 (TAAR1) agonist which is under development for the treatment of schizophrenia and Alzheimer's disease.[2][3] It is taken orally as a controlled-release formulation. The drug is under development by Luye Pharma Group.[2][3] As of February 2026, it is in phase 1 clinical trials for both indications.[2][3] The chemical structure of LY03020 does not yet appear to have been disclosed.

See also

[edit]

References

[edit]
  1. 1 2 3 "Delving into the Latest Updates on LPM787000048 with Synapse". Synapse. 9 February 2026. Retrieved 27 March 2026.
  2. 1 2 3 Sami T (27 March 2026). "Luye advances dual agonist for schizophrenia, Alzheimer's". BioWorld. Retrieved 27 March 2026.
[edit]
Retrieved from "https://en.wikipedia.org/w/index.php?title=LY03020&oldid=1345800285"